We are live on
!
Find out more
Ultragenyx Pharmaceutical
RARE
RARE
287 hedge funds and large institutions have $2.16B invested in Ultragenyx Pharmaceutical in 2025 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 111 increasing their positions, 91 reducing their positions, and 65 closing their positions.
New
Increased
Maintained
Reduced
Closed
60% more call options, than puts
Call options by funds: $75.9M | Put options by funds: $47.6M
22% more repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 91
1.7% less ownership
Funds ownership: 99.08% → 97.37% (-1.7%)
5% less funds holding
Funds holding: 302 → 287 (-15)
12% less first-time investments, than exits
New positions opened: 57 | Existing positions closed: 65
25% less capital invested
Capital invested by funds: $2.87B → $2.16B (-$710M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Holders
287
Holders Change
-15
Holders Change %
-4.97%
% of All Funds
3.49%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
57
Increased
111
Reduced
91
Closed
65
Calls
$75.9M
Puts
$47.6M
Net Calls
+$28.3M
Net Calls Change
-$25.9M
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$65.6M |
| 2 |
Morgan Stanley
New York
|
+$30.1M |
| 3 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$29.5M |
| 4 |
Millennium Management
New York
|
+$25.7M |
| 5 |
Jane Street
New York
|
+$21.9M |
